남성 불임증 : 질환 분석과 예측

GlobalData forecasts that the diagnosed prevalent cases of male infertility are expected to slightly decline from 3,957,575 cases in 2025 to 3,932,895 cases in 2035, at a negative annual growth rate (AGR) of 0.06% across the seven major pharmaceutical markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan).

Male infertility is a medical condition, including disorders such as oligo-,astheno-, terato-, and azoospermia. The condition has low prevalence and can be caused by numerous factors, including genetics, environmental, or as a symptom of another disease.

Scope

• Overview of male infertility, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized male infertility therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2025 to 2035.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the male infertility therapeutics market.
• Pipeline analysis: data assessing emerging trends and mechanisms of action under development for male infertility treatment. Any late stage pipeline therapeutics are mapped.
• Analysis of the current and future market competition in the global male infertility therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop business strategies by understanding the trends shaping and driving the 7MM male infertility therapeutics market.
• Drive revenues by understanding the key trends, market segments, and companies likely to impact the 7MM male infertility therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and usage of generic therapeutics.
• Understand the challenges facing the male infertility therapeutics market from clinical and environmental perspectives
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1. Preface

• 1.1. Contents
• 1.2. Abbreviations
• 1.3. Related Reports

2. Executive Summary

3. Disease Overview

• 3.1. Overview of Male Infertility
• 3.2. Male Infertility Strengths, Weaknesses, Opportunities, and Threats Analysis
• 3.3. Classification of Male Infertility
• 3.4. Diagnosis of Male Infertility

4. Epidemiology

• 4.1. Diagnosed Prevalent Cases of Male Infertility, Men, N, Ages 15-49 Years, 2025-35
• 4.2. Age-Specific Diagnosed Prevalent Cases of Male Infertility, N, Men, Ages 15-49 Years, 2025
• 4.3. Diagnosed Prevalent Cases of Oligozoospermia, N, Men, Ages 15-49 Years, 2025

5. Current Treatment Options

• 5.1. Treatment Paradigm
• 5.2. Current Treatment Options
• 5.3. Product Profile: Menotropin
• 5.4. Product Profile: Chorionic Gonadotropin
• 5.5. Product Profile: Mesterolone
• 5.6. Product Profile: Urofollitropin
• 5.7. Product Profile: Clomiphene citrate
• 5.8. Current Treatment Options: KOL Perspectives

6. Unmet Needs and Opportunities

• 6.1. Unmet Needs in Male Infertility
• 6.2. Overall Lack of Pharmacological Therapies in Male Infertility
• 6.3. Knowledge Gaps in Causes of Male Infertility
• 6.4. Prioritization of Female Treatments for Infertility
• 6.5. Difficulty in Recruitment for Clinical Trials

7. R&D Strategies

• 7.1. Trends in Deal-Making in Male Infertility
• 7.2. Trends in Clinical Trial Design in Male Infertility

8. Pipeline Assessment

• 8.1. Male Infertility Pipeline Overview
• 8.2. Late Stage Pipeline Agents for Male Infertility
• 8.3. Product Profile: Prokrea's Pentoxifylline
• 8.4. Male Infertility Late-Stage Clinical Trials by Phase

9. Market Outlook

• 9.1. Male Infertility Market Forecast
• 9.2. Male Infertility by Drug and Classes, 2025 and 2035
• 9.3. Market Drivers and Barriers

10. Appendix

• 10.1. Bibliography
• 10.2. About the Authors

11. Contact Us